Fundraising Fox

Tune Therapeutics

Durham and Seattle, US · Founded 2020 · Delaware corporation · 64 employees on LinkedIn · 7 known investors

Tune Therapeutics develops a therapeutic platform targeting the epigenome to treat complex diseases and regenerative medicine applications. The company works on novel gene network therapies for challenging diseases.

BiotechDeep TechHealthtechLongevityMedical Devices

Founders & leadership

Tune Therapeutics was founded in 2020 by Akira Matsuno, Derek Jantz, and Charles Gersbach.

AMAkira Matsuno
Akira MatsunoCo-founder
DJDerek Jantz
Derek JantzinCo-founder
CGCharles Gersbach
Charles GersbachinCo-founder
JMJohn McHutchison
John McHutchisonCEO, Chairman of the Board
DMDan McHugh
Dan McHughExecutive
BSBlythe Sather
Blythe SatherExecutive
YZ
Yuan ZhangExecutive
ZHZachary Hale
Zachary HaleExecutive

Board

ABAli Behbahani
Ali BehbahaniinBoard directorPartner, Co-Head of Healthcare at New Enterprise Associates (NEA)

Investors · 7

Duke Capital PartnersDurham
Mission BiocapitalSan Francisco · $500K
New Enterprise Associates (NEA)Menlo Park · $200K – $40Mvia Ali Behbahani · board
Hatteras Venture PartnersreportedResearch Triangle · $500K – $4M
Yosemitereported · 2 sourcesSan Francisco

Also in the syndicate · 2

Hevolution FoundationleadRegeneron Ventureslead

Funding

SEC filings, press & company announcements

$357.4M disclosed across 2 rounds · 2023–2025

▶$182.4MraisedJan 2025 · 39 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Dan McHughExecutive Officer, Director
  • Akira MatsunoExecutive Officer
  • Blythe SatherExecutive Officer
  • Derek JantzExecutive Officer
  • Charles GersbachDirector
  • John McHutchisonDirector
  • Yuan ZhangExecutive Officer
  • Zachary HaleExecutive Officer
  • Ali BehbahaniDirector
Offering amount
$208M
Amount sold
$182.4M
First sale
Mar 2023
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Durham’s Tune Therapeutics raises $175 million for novel trial | Raleigh News & Observernewsobserver.com · Jan 2025Tune Therapeutics Completes Over $175M in Series B Financingfinsmes.com · Jan 2025Epigenetic biotech raises bumper round to the Tune of $175M to fund entry into clinicfiercebiotech.com · Jan 2025Durham biotech firm Tune Therapeutics has raised a $175 million funding roundaxios.com · Jan 2025Tune Therapeutics raises $175M Series B for epigenetic editingendpoints.news · Jan 2025

Frequently asked questions

What does Tune Therapeutics do?
Tune Therapeutics develops a therapeutic platform targeting the epigenome to treat complex diseases and regenerative medicine applications. The company works on novel gene network therapies for challenging diseases.
Who founded Tune Therapeutics?
Tune Therapeutics was founded by Akira Matsuno, Derek Jantz, Charles Gersbach in 2020.
Who are Tune Therapeutics's investors?
Tune Therapeutics's investors include Duke Capital Partners, Mission Biocapital, New Enterprise Associates (NEA), Hatteras Venture Partners, Yosemite.
How much funding has Tune Therapeutics raised?
Tune Therapeutics has disclosed $357.4M raised across 2 rounds.
Where is Tune Therapeutics headquartered?
Tune Therapeutics is headquartered in Durham and Seattle, US.